June 29 (Reuters) – Lipocine Inc said its oral
testosterone replacement product did not get the approval in the
United States, sending the drugmaker’s shares down 56 pct in
premarket trading.
The post Lipocine says U.S. FDA does not approve its testosterone product appeared first on NASDAQ.